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ABSTRACT: The covalent addition of ubiquitin to target proteins
is a key post-translational modiﬁcation that is linked to a myriad of
biological processes. Here, we report a fast, single-molecule, and
label-free method to probe the ubiquitination of proteins
employing an engineered Cytolysin A (ClyA) nanopore. We
show that ionic currents can be used to recognize mono- and
polyubiquitinated forms of native proteins under physiological
conditions. Using deﬁned conjugates, we also show that isomeric
monoubiquitinated proteins can be discriminated. The nanopore
approach allows following the ubiquitination reaction in real time,
which will accelerate the understanding of fundamental mechanisms linked to protein ubiquitination.
KEYWORDS: nanotechnology, nanopore, single-molecule kinetics, protein modiﬁcations, ubiquitin
Post-translational modiﬁcations (PTMs) regulate thefunction of a vast range of proteins in a eukaryoticcell. The attachment of the small 8.6 kDa protein
ubiquitin (Ub) to a substrate protein (ubiquitination) can aﬀect
its fate in many ways, from signaling its degradation to altering
its cellular location or inhibiting its interaction with other
proteins. Ubiquitination is achieved through the activity of
three diﬀerent enzymes.1,2 First, an ubiquitin activating enzyme
(E1) activates Ub through the hydrolysis of ATP. Next, the E1
transfers Ub to the active site cysteine of a ubiquitin-
conjugating enzyme (E2), which, with the aid of an E3 ligase,
attaches Ub to a substrate protein, often to a lysine residue
(Figure 1A).
Abnormal concentration of ubiquitin and/or the precise
ubiquitination of protein substrates are linked to disease. For
example, ubiquitin levels have been observed to increase in
cerebrospinal ﬂuid of patients with Alzheimer’s disease,3 while
ubiquitinated substrates, including E2 enzymes, are directly
implicated in human disease.4 Further, aberrant ubiquitination
of α-synuclein, a protein involved in Parkinson’s disease, may
aﬀect aggregation depending on which lysine residue is
modiﬁed.5 It follows that the detection of the exact pattern
and position of ubiquitination of a protein substrate is a
potentially useful biomarker for disease onset and progres-
sion.6,7
Currently, only ensemble methods that use either
ﬂuorescently labeled ubiquitin8 or substrates9 allow real-time
monitoring of the ubiquitination reaction in vitro. Such
methods, however, do not allow monitoring the entire
ubiquitination cascade of E1−E2−E3 or the simultaneous
modiﬁcation of multiple substrates. Further, since ubiquitina-
tion relies on precise interactions between proteins, ﬂuorescent
substrates often alter the kinetics and eﬃciency of the
ubiquitination reaction.10 Therefore, single-molecule and
label-free methods can enhance our understanding of the
factors that regulate ubiquitination.
Biological nanopores are powerful tools to study single
molecules. In nanopore analysis, the signal is provided by the
ionic current generated by hydrated ions translocating through
the nanopore under an external applied potential. Molecules
entering the nanopore by either passive diﬀusion or sustained
by the electrical potential or the electro-osmotic ﬂow are
recognized by the speciﬁc modulation of the nanopore current.
Nanopores have been used to sense molecules11−14 and to
monitor chemical and enzymatic reactions15−18 to study nucleic
acids19−22 and folded proteins.23−27 Unfolded proteins might
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also be studied as they translocate through nanopores with 1−2
nm of diameter.27−32
The identiﬁcation of large PTMs such as ubiquitination may
be achievable directly with nanopores. Using an immobilized
DNA-conjugated model protein Bayley and co-workers showed
that phosphorylation, another PTM, can be identiﬁed at
diﬀerent sites in unfolded polypeptides threading the nano-
pore.33 However, at the moment, the unassisted translocation
of polypeptides is too fast to allow the sequence identiﬁcation
of individual amino acids on the ﬂy. Recently, Meller and co-
workers demonstrated the detection and discrimination of
single ubiquitin as well as short ubiquitin polymers with solid-
state nanopores,34 which may be useful to study length and
linkage-type of ubiquitin chains once removed from a protein of
interest. We have shown that folded proteins can be studied
with the biological nanopore Cytolysin A (ClyA).13 Because the
5.5 nm cis opening of ClyA is larger than its trans opening (3.3
nm, Figure 1B), proteins can remain trapped inside the
nanopore for extensive time (i.e., from milliseconds to hours
depending on the size, charge, and shape of the protein)13 and
consequently recognized by the speciﬁc modulation of the
nanopore current. In this work, we investigated the ability of
nanopores to detect mono- and polyubiquitinated proteins.
Using an engineered ClyA nanopore, we show that nanopore
currents can be used to discriminate a protein from its mono-
and polyubiquitinated derivatives and to discriminate deﬁned
isomeric monoubiquitinated proteins. Notably, all recordings
employed physiological conditions (Tris-buﬀered saline buﬀer:
150 mM NaCl, 50 mM TrisHCl, pH 7.5), sampled native
proteins and allowed determining kinetic parameters of the E1
enzyme by observing the formation of the ubiquitinated E2
protein in real time. Collectively, our data put biological
nanopores forward as a single-molecule tool for the detection
and analysis of protein ubiquitination in vitro.
RESULTS AND DISCUSSION
Detection of Mono- and Poly-Ub Conjugates with an
Engineered Biological Nanopore. To investigate whether
ClyA can discriminate between a protein and its ubiquitinated
form(s), we chose the ubiquitin-conjugating enzyme Ubc4
from the yeast Saccharomyces cerevisiae as a model protein. We
relied on the fact that this E2 can ubiquitinate itself in vitro.35
Many E2 enzymes are able to self-ubiquitinate, which might act
as a regulator of E2 activity.36 We employed this behavior to
produce ubiquitinated protein in large amounts. In addition, we
reasoned that the molecular weight of Ubc4 (19.8 kDa) and its
ubiquitinated derivatives (+8.6 kDa) would be suitable for
detection with ClyA nanopores (Figure 1B). We ﬁrst added
recombinantly expressed and puriﬁed Ubc4 (hereafter E2)
(Figure S1A) to the cis side of a type I ClyA-AS37 nanopore
(C87A/L99Q/E103G/F166Y/I203V/C285S/K294R/H307Y),
in a buﬀer containing 500 μL of 150 mM NaCl, 50 mM
TrisHCl, pH 7.5, and applied a transmembrane potential of
−35 mV (referring to the trans or “working electrode”). The
Figure 1. (A) Scheme of the ubiquitin cascade. Ubiquitin activating enzyme (E1) activates Ub through hydrolysis of ATP. Next, the E1
transfers Ub to the active site cysteine of a ubiquitin-conjugating enzyme (E2). E2 can transfer Ub further to one of its lysine residues or, with
the help of a ubiquitin ligase (E3), ubiquitinate substrates (S). The part of the cascade above the dashed line we exploited to create E2 and its
ubiquitinated form. (B) Left: ClyA nanopore (orange) from Salmonella typhi47 lodged inside a lipid bilayer (gray) composed of 1,2-dioleoyl-
sn-glycero-3-phosphocholine. Asterisks mark the approximate position of the glutamine to tryptophan substitution (Q56W). On the right are
surface representations of the E2 Ub-conjugating enzyme Ubc4 (E2, cyan, PDB: 1QCQ) of Saccharomyces cerevisiae shown with and without
Ub (green, PDB: 3CMM). The E2Ub conjugate models were constructed with PyMOL. The larger opening of ClyA is facing the cis
compartment, whereas trans denotes the location of the “working” electrode. (C) Representative trace obtained with ClyA-AS after addition
of the E2 enzyme (50 nM) added to the cis side of the nanopore. (D) E2 (50 nM) blockades elicited to ClyA-56W. IO denotes the
unobstructed open pore current; IB is the blocked pore current as E2 dwells inside ClyA. Data in (C) and (D) were collected in 150 mM NaCl,
50 mM TrisHCl, pH 7.5 at −35 mV potential applied to the trans electrode and recorded using a 2 kHz low-pass Bessel ﬁlter with a 10 kHz
sampling rate. Traces were postacquisition digitally ﬁltered with a Gaussian 500 Hz low-pass ﬁlter.
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same buﬀer and applied potential were used throughout this
study. We observed blockades (Figure 1C) with a residual
current (Ires%), deﬁned as the ratio of amplitude percent of
blocked pore (IB) and open pore (IO), of 72.9 ± 4.5%, with an
average dwell time (or τoff) of 39 ± 24 ms (mean ± SD; the
mean and SD are obtained from N = 3 independent nanopore
experiments, (Supporting Information Table 1). To prolong
dwell times and thus potential resolution of isomeric
ubiquitinated substrates, we used an engineered ClyA-AS
nanopore where a tryptophan substituted a glutamine at
position 56 (ClyA-Q56W, manuscript in preparation). Hence,
an increased hydrophobic inner surface is created inside the
lumen of ClyA-56W that would allow hydrophobic and
electrostatic π interaction of proteins with the nanopore.
Addition of 50 nM E2 to the cis side of ClyA-56W (henceforth
ClyA, Figure 1D and Figure S1B) increased dwell times to 1737
± 420 ms with similar Ires% of 74.0 ± 0.8% (N = 3), suggesting
that E2 interacts with the inner surface of ClyA near position
56. The average capture rate (kc), the inverse of the interevent
time normalized for 1 μM of analyte, was 21.7 ± 3.6 s−1 μM−1.
In order to obtain E2Ub conjugates, we performed in vitro
ubiquitination reactions. As a negative control, we performed
reactions in the absence of ATP. In those reactions, no
ubiquitinated E2 was produced, as determined by SDS-PAGE
and Coomassie staining (Figure 2). Addition of 5 μL of such a
reaction mixture containing no ATP to the 500 μL cis
compartment of nanopores resulted in the formation of a
single type of blockade, similar to the E2 alone, with Ires% 75.4
± 0.3% (N = 3, τoff = 2231 ± 481 ms, kc = 6.6 ± 0.7 s
−1 μM−1
(Figure 3A); thus the E1 and Ub do not produce blockades
under these experimental conditions with ClyA. Consistently,
we did not observe blockades when adding E1 and Ub in the
absence of E2 (Figure S2). Therefore, E1 (molecular weight =
110 kDa) most likely is too large to enter the nanopore,
whereas Ub (molecular weight = 8.6 kDa) molecules
translocate too rapidly through ClyA. In support of this, we
previously observed only very short transient events for
lysozymes (molecular weight = 15 kDa).13
When ATP was present in in vitro ubiquitination reactions,
eﬃcient E2 self-ubiquitination was occurring, as determined by
SDS-PAGE and Coomassie staining (Figure 2). The major
product of the reaction was monoubiquitinated E2, but a small
amount of E2 carrying two Ubs was also produced, in line with
our previous data.35 When 1:100 dilutions of such reactions
were probed with nanopores, three blockade types were
observed (Figure 3B). Blockade B1 (Ires% = 73.9 ± 0.2%, N =
3, τoff = 898 ± 198 ms) corresponds to the E2 alone, as it
showed the same current blocked level observed for
recombinant E2 (Figure S1B) and in vitro ubiquitination
reactions lacking ATP (Figure 3A). Blockades B2 (Ires% = 64.0
± 0.7%, N = 3, τoff = 1602 ± 626 ms) and B3 (Ires% = 51.8 ±
0.8%, N = 3, τoff = 1930 ± 764 ms) therefore represent
ubiquitinated forms of the E2, with B2 likely corresponding to
monoubiquitinated E2 (E2Ub) and B3, displaying a broader
distribution of residual currents, corresponding to an E2
carrying two Ubs (E2Ub2) (Figure 3B).
Our labeling of these latter two species, B2 and B3, rests on
two observations: volume exclusion consideration suggests that
deeper blockades (as determined by a lower Ires% value) should
correspond to a larger protein inside ClyA; hence B3 should
Figure 2. Coomassie-stained 15% SDS-PAGE gel of an E2
ubiquitination reaction with and without ATP. Protein marker
(kDa) is shown on the left; the middle lane shows a ubiquitination
reaction lacking ATP and on the right is a ubiquitination reaction
shown with 5 mM ATP present. Both reactions were incubated for
2.5 h at 35 °C with shaking in buﬀer containing 75 mM NaCl, 25
mM TrisHCl, pH 8, 5 mM MgCl2, recombinant Ub (12 μM),
activating enzyme (E1, 0.4 μM), and E2 (6 μM). Depicted on the
right of the gel is the intensity proﬁle of the in vitro reaction
ranging from beneath E2 to above E2Ub2 with arbitrary absorbance
units as determined with ImageJ (NIH).
Figure 3. Detection of protein ubiquitination with ClyA nanopores.
(A) From top to bottom: Representative trace (IO = open pore and
IB1 = blockade level, both at −35 mV), zoom-ins, histogram, and
residual current percent (Ires%) versus the standard deviation (SD)
of individual current blockades elicited by E2 proteins. The
blockades appeared after adding a 1:100 dilution (ﬁnal) of the in
vitro ubiquitination reaction described in Figure 2 (not containing
ATP) to the cis side of the nanopore. (B) Same as in (A), but the
ubiquitination reaction contained ATP. Note that Ub and E1 do
not elicit blockades (Figure S1). Buﬀer used in all electro-
physiological experiments: 150 mM NaCl, 50 mM TrisHCl, pH
7.5. Data were collected at −35 mV and recorded using a 2 kHz
low-pass Bessel ﬁlter with a 10 kHz sampling rate. Traces were
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represent a larger molecular weight species than B2. Second,
ratios of the nanopore observed blockades (39 ± 2% B1, 46 ±
3% B2, 15 ± 1% B3) match reasonably well with data obtained
from quantiﬁcation of the Coomassie-stained SDS-PAGE gel
(Figure 2) of the same in vitro reaction (47% E2, 47% E2Ub,
5% E2Ub2). The diﬀerences between the two measurements
might reﬂect diﬀerent capture eﬃciencies between E2 and E2
conjugates and the semiquantitative nature of protein
quantiﬁcations from Coomassie-stained gels. Thus, our data
demonstrate that ClyA can directly discriminate between a
protein and its mono- and poly-Ub conjugates.
ClyA Can Discriminate between Two Isomeric E2Ub
Conjugates. We observed that the blockades of E2Ub (and
E2Ub2) of the in vitro reaction were wider in their distribution
of residual current when compared to those of E2 alone (i.e.,
the peak is wider, Figure 3B, histogram). We postulated that
this may be due to the presence of isomeric forms of E2Ub.
Isolation of the Coomassie-stained band from SDS-PAGE
corresponding to E2Ub, followed by mass spectrometry (Figure
S3), identiﬁed three potential ubiquitination sites on the E2
(lysine residues 35, 39, and 121). These data conﬁrmed the
presence of at least three isomeric forms of E2Ub in our
samples, although their relative concentration could not be
assessed.
To investigate if nanopores can be used to discriminate
between two isomeric E2Ub molecules, we sought to create
well-deﬁned E2Ub conjugates. This was achieved by exchang-
ing the active site cysteine residue of the E2 for a lysine,
creating E2-C116K (henceforth E2*). Such mutant E2s can
accept Ub from the E1 on the active site (albeit at a reduced
rate) but are unable to transfer the Ub further, creating a
homogeneously ubiquitinated E2.38 On a Coomassie-stained
SDS-PAGE gel, we detected only a single major upper band
(Figure S1A) corresponding to E2* monoubiquitinated on
residue 116 (E2*Ub). Adding 10 μL of in vitro ubiquitination
reaction of E2* to ClyA (1:50 dilution, Figure 4A) resulted in
Figure 4. Discrimination of isomeric E2Ub conjugates. (A) From top to bottom: Surface representation of the E2 mutant (C116K, E2*) and
E2* conjugated to Ub at its active site (E2*Ub, constructed with PyMOL) with below given a continuous representative trace of the in vitro
ubiquitination reaction of E2* analyzed with ClyA nanopores (IO = open pore, IB1 = blockade level elicited by E2, IB2 = E2*Ub); zoom-ins for
blockades elicited by E2 and E2Ub; contour plot of all obtained blockades of an experiment. The same in vitro ubiquitination reaction was run
on a Coomassie gel (lane 4, Figure S1A); a 1:50 dilution, or 120 nM E2*/E2*Ub, was used in experiments with the nanopore). (B) From top
to bottom: Surface representation of N-terminally fused E2Ub protein (UbE2), constructed with PyMOL, and below a representative trace of
200 nM puriﬁed UbE2 analyzed with ClyA nanopores (IB3 = blockade level elicited by UbE2); zoom-ins provided for two blockades of UbE2;
and blockades of an experiment depicted as a contour plot. (C) From top to bottom: Surface representation of E2*, E2*Ub, and UbE2; the
proteins analyzed here in a mixture. Below are the same plots as in A and B shown but with 100 nM UbE2 and 1:50 dilution of an in vitro
reaction (thus about 120 nM of E2* or E2*Ub) added to the cis side. Buﬀer used in all experiments: 150 mM NaCl, 50 mM TrisHCl, pH 7.5.
Data were recorded using a 2 kHz low-pass Bessel ﬁlter with a 10 kHz sampling rate. All traces shown were postacquisition digitally ﬁltered
with a 500 Hz Gaussian low-pass ﬁlter.
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blockades corresponding to the unmodiﬁed E2 (B1, Ires% = 73.5
± 0.1%, N = 3, τoff = 503 ± 103 ms) as well as in 30% of the
cases extra blockades that displayed Ires% values and dwell times
(Ires% = 63.2 ± 0.1%, N = 3, τoff = 2105 ± 600 ms) similar to
those of E2Ub conjugates (Figure 3B). To create a second well-
deﬁned E2Ub conjugate, we fused Ub genetically to E2 at its N-
terminus (UbE2) and expressed the construct recombinantly.
E2*Ub and UbE2 were thus isomeric proteins, apart from the
active site cysteine in UbE2 which is a lysine in E2*Ub. It
should be noted that the exchange of cysteine for a lysine did
not alter the blockades observed for E2* and E2 (Figures 3A
and 4A). SDS-PAGE and Coomassie staining of E2*Ub and
recombinantly puriﬁed UbE2 (Figure S4) demonstrated that
both proteins ran almost identically on gel, making them
virtually impossible to separate by this technique.
UbE2 (200 nM) showed blockades (Figure 4B) with, on
average, similar residual currents as E2*Ub (Ires% = 62.5 ±
1.8%, N = 3, τoff = 307 ± 126 ms, kc = 16.7 ± 1.7 s
−1 μM−1) but
wider in their distribution (Figure 4A). Further, the average
dwell time was ∼4-fold shorter than that for E2*Ub, enabling,
partially, the discrimination of both isoforms by plotting the
dwell time over the residual current (Figure S5). We also
noticed that UbE2 blockades displayed a signiﬁcantly higher SD
of the current amplitude when compared to those caused by
E2*Ub. The signals from the two isomeric species could be
reliably separated by expressing the SD of the amplitude versus
the residual current of the blockades caused by each species
(Figure 4C, bottom). Taken together, our data demonstrate
that ClyA can discriminate between isomeric E2Ub conjugates.
Real-Time Observation of Protein Ubiquitination
under Physiological Conditions. Our data suggest that the
Figure 5. Real-time observation of protein-ubiquitination with the ClyA nanopore. (A) Representative traces from a real-time ubiquitination
reaction further analyzed in (B) and (C). E1 (26.6 nM), E2 (160 nM), Ub (320 nM), and MgCl2 (5 mM) are present in the cis buﬀer (150 mM
NaCl, 50 mM TrisHCl, pH 7.5, ∼23 °C). Blockades corresponding to E2Ub appear within 1 min and become the dominant type of events
within 10 min. (B) All blockades individually represented as dots versus time. (C) Determination of the rate of E2 disappearance. The
concentration of E2 was measured from the frequencies of current blockades as described in the Methods section. Linear ﬁts (Origin,
OriginLab, thin line) were used to determine the initial rate of the reaction. Data were collected at −35 mV using a 2 kHz low-pass Bessel
ﬁlter with a 10 kHz sampling rate.
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nanopore system can be employed to observe the kinetics of
ubiquitination of E2 in real time. Using the same physiological
buﬀer mixture as used for analyzing end-point reactions, we
added 5 mM MgCl2, 1 mM DTT, E1 (26.6 or 5.3 nM), Ub
(320 nM), and E2 (160 nM) proteins to the cis side of ClyA. As
expected, we observed only blockades corresponding to E2
from reactions performed without ATP. When we added 5 mM
ATP to the same side, blockades corresponding to E2Ub
appeared almost immediately, with the reaction reaching a
plateau after 10−15 min (Figure 5 and Figure S6) when 26.6
nM E1 was present. The dwell time of E2 and E2Ub was
shortened to 356 ± 154 and 528 ± 271 ms (N = 6, combined
for reactions containing either 26.6 or 5.3 nM E1), respectively,
most likely to the eﬀect of MgCl2 concentrations. The observed
rate of the reaction could be obtained by following either the
disappearance of E2 blockades or the appearance of E2Ub
blockades (Figure 5B). We used the frequency of E2 blockades
to measure the concentration of E2 in solution (Figure 5C and
Figure S6; Methods). The slope of the linear regressions to the
initial rates of E2 disappearance, −10.1 ± 3.9 nM min−1, gave
the rate of the loading of E1 with Ub under hydrolysis of ATP
and the transfer of Ub to E2 from the E1 enzyme. As expected
for an enzymatic reaction, decreasing E1 to 5.3 nM reduced the
rate of the reaction accordingly to −1.1 ± 0.3 nM min−1
(Figure S6). In contrast to in vitro reaction experiments
monitored by gel electrophoresis, even after 3 h, we only
observed very few blockades which could be attributed to E2
carrying two ubiquitin molecules, an eﬀect most likely due to
the much reduced concentration of reactants used in the
nanopore experiments. Taken together, our data show that
nanopores can be employed to follow the ubiquitination
cascade at the single-molecule level in real time.
CONCLUSION
The function of many proteins is regulated by ubiquitination:
the covalent attachment of ubiquitin to substrate protein side
chains. Since aberrant ubiquitination has been related to
disease,4 the detection of diﬀerent ubiquitinated species in
biological samples could help monitoring the onset of diseases.
Commonly, gel electrophoresis is employed to detect and
separate proteins in their mono- and polyubiquitinated forms,
whereas mass spectrometry is the method of choice for
detecting and characterizing ubiquitination de novo. Such
techniques, however, are expensive and/or require lengthy
preparation procedures. In this work, we showed that a
biological nanopore can be employed to resolve protein and
protein−ubiquitin adducts. Using deﬁned monoubiquitin
proteins, we could demonstrate that ClyA can resolve also
isomeric ubiquitin-carrying proteins. Therefore, the ClyA
nanopores could provide a low-cost method to monitor
aberrant ubiquitination in a biological sample. However,
similarly to all analytical techniques used in proteomics, the
identiﬁcation of proteins in complex biological samples will
most likely require suppressing the signal from background
proteins. This could be achieved, for example, using selective
binding molecules to enrich target ubiquitinated proteins near
the nanopore mouth,13 while current recordings will be used to
detect and quantify subpopulations of target proteins.
We also showed that the nanopore system is able to monitor
the ubiquitination of native proteins in real time under
physiological conditions. In vitro kinetic analysis of post-
translational modiﬁcations is often challenging because the
covalent modiﬁcation of proteins is usually not associated with
a change in a spectroscopic signal. For example, ubiquitination
may only be monitored in real time using the change in
ﬂuorescence polarization that follows the conjugation of a
ﬂuorescently labeled ubiquitin to its substrate.39 Labeled
ubiquitin, however, may alter aﬃnity with substrate proteins
while the ﬂuorescent signal cannot distinguish between
diﬀerent ubiquitinated proteins, hence precluding monitoring
intermediates and the E1−E2−E3 ubiquitination cascade.
Crucially, because the signal allows recognition and discrim-
ination of single proteins, the nanopore approach should allow
following reaction intermediates and the simultaneous ubiq-
uitination of diﬀerent substrates. Thus, the nanopore approach
could be expanded to follow, for example, the transfer of Ub
from E2 to HECT domain E3s and even to substrates,
following eﬀectively the whole cascade concomitantly. This has
potential applications when measuring the eﬀect of small-
molecule40 and peptide41 inhibitors or binding partners35 of a
certain component of the Ub cascade upon the whole
ubiquitination cascade. Also, pathways that involve ubiquitin-
like proteins such as SUMO, NEDD8, or ISG1542 could be
studied with the nanopore approach. Taken together, here we
introduce a nanopore method that is immediately applicable to
follow the ubiquitination of proteins of about 20−50 kDa in
size. Solid-state or biological nanopores with wider diameters
might be employed to monitor larger proteins.
METHODS
Plasmid Construction, Protein Expression, and Puriﬁcation.
In this work, we used an engineered variant of ClyA from Salmonella
typhi, ClyA-AS (C87A/L99Q/E103G/F166Y/I203V/C285S/K294R/
H307Y), as a template for the preparation of a ClyA variant containing
a ring of tryptophan residues at position 56. The rationale behind this
is that a ring of bulky, hydrophobic residues in the nanopore lumen
might promote the target protein to dwell longer in the pore because
of a smaller diameter of the pore and stronger interaction with the
lumen.
The ClyA-AS-Q56W variant was prepared according to the
MEGAWHOP procedure.43 Part of the ClyA gene was ampliﬁed
using the primer containing the Q56W substitution (forward, 5′-
GAATACAGTTGGGAAGCGTCC-3′) and the T7 promotor (re-
verse, 5′-GCTAGTTATTGCTCAGCGG-3′). REDTaq ReadyMix
(150 μL) was mixed with 6 μM of forward and reverse primers and
∼400 ng of plasmid template, and PCR water was added to reach a
ﬁnal volume of 0.3 mL. After a preincubation step at 95 °C for 3 min,
the reaction was cycled 27 times according to the cycling protocol:
denaturation at 95 °C for 15 s, annealing at 55 °C for 15 s, extension at
72 °C for 2 min. The resulting PCR product was concentrated using
the QIAquick PCR puriﬁcation kit (Qiagen) and gel-puriﬁed using the
QIAquick gel extraction kit. About 500 ng of the puriﬁed PCR product
was mixed with ∼300 ng of the ClyA-AS DNA template and the
ampliﬁcation was carried out with Phire Hot Start II DNA polymerase
in 50 μL ﬁnal volume. After 30 s preincubation at 98 °C, the reaction
was cycled 30 times according to the following cycling protocol:
denaturation at 98 °C for 5 s, extension at 72 °C for 1.5 min. The
circular template was eliminated by incubation with Dpn I (1 FDU)
for 1 h at 37 °C. Next, 0.6 μL of the resulting mixture was transformed
into 50 μL of E. cloni 10G cells (Lucigen) by electroporation. The
transformed bacteria were grown overnight at 37 °C on ampicillin
(100 μg/mL) LB agar plates. The identity of the clones was conﬁrmed
by sequencing.
ClyA-AS and ClyA-AS-Q56W contain a C-terminal hexa-histidine
tag. Monomers were expressed in E. cloni EXPRESS BL21 (DE3) cells
(Lucigen) and puriﬁed using Ni-NTA aﬃnity chromatography as
described before.37 Oligomers were then formed by adding 0.2% n-
dodecyl-β-D-maltoside (DDM, GLYCON Biochemicals GmbH). Type
I ClyA oligomers were separated from monomers and several other
oligomeric ClyA forms37 using a blue-native polyacrylamide gel
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electrophoresis (BN-PAGE, Bio-Rad). In this work, we gel-extracted
the lowest band, which is likely to correspond to the 12-meric (Type
I) form of ClyA. Aliquots were stored at 4 °C in 150 mM NaCl, 15
mM Tris.HCl, pH 7.5 supplemented with 0.2% DDM and 10 mM
EDTA.
The active site mutant form of Ubc4p (E2*) was constructed using
the Quikchange site-directed mutagenesis kit (Stratagene), using the
primer pair Ubc4 C-K F (5′-ATCAATGCCAATGGTAACAT-
CAAACTGGACATCCTAAAGGATCAATG-3′) and Ubc4 C-K R
(5′-CATTGATCCTTTAGGATGTCCAGTTTGATGTTAC-
CATTGGCATTGAT-3′). The plasmid for expressing Ub fused to the
N-terminus of Ubc4 (UbE2) was constructed as follows: UbE2 was
synthesized as gBlock DNA fragment (Integrated DNA Technolo-
gies), digested with NcoI and BamHI, and cloned into NcoI-BamHI
cut pET15b. Wild-type and mutant forms of Ubc4p were expressed
and puriﬁed as described previously.44 Human E1 (Ube1) was
expressed and puriﬁed as described before.45
In Vitro Ubiquitination Reactions. In vitro ubiquitination
reactions were performed essentially as described previously.44
Reactions were performed in 25 mM TrisHCl, pH 8, 75 mM NaCl,
5 mM MgCl2, containing 0.4 μM E1 (Ube1), 6 μM E2 (Ubc4), and 12
μM Ub (BostonBiochem) with or without 5 mM ATP. Reactions with
wild-type E2 were incubated for 2.5 h at 35 °C with 800 rpm shaking,
whereas reactions of the active site mutant form of the E2 (E2*) were
incubated for 16 h at 35 °C with shaking. For SDS-PAGE and
Coomassie staining, samples were quenched with SDS-PAGE buﬀer
containing 5% β-mercaptoethanol and heated for 5 min at 95 °C prior
to loading on a 15% SDS-PAGE gel.
Image Densitometry with ImageJ. For analysis of the
Coomassie-stained gel, the ImageJ function “Plot Proﬁle” was used.
After subtraction of the image background (rolling ball radius, 50
pixels), a line was drawn across the bands of interest and the “Plot
Proﬁle” function used. The resulting values were used to create a
histogram in Clampﬁt (Molecular Devices) where Gaussian functions
were ﬁtted and the area under the curve was used to determine the
relative percentages of the peaks.
Electrophysiological Recordings and Data Analysis. An
aperture of about 100 μm in diameter was created in a polytetraﬂuoro-
ethylene ﬁlm (Goodfellow Cambridge Limited) by applying a high-
voltage spark. After application of a drop (∼10 μL) of a 5%
hexadecane/pentane solution to the aperture and a short waiting
period, in order to allow pentane to evaporate, 500 μL of buﬀer in 150
mM NaCl, 50 mM TrisHCl, pH 7.5, was added to both sides of the
ﬁlm. A drop of about 10 μL of 10 mg/mL 1,2-diphytanoyl-sn-glycero-
3-phosphocholine (DPhPC, Avanti Polar Lipids), dissolved in
pentane, was then added on top of the buﬀer on both sides. After
pipetting up and down, a folded bilayer formed spontaneously with a
capacitance between 80 and 150 pF, depending on the electro-
physiological chamber used. Normally, the capacitance varies only
slightly for a given chamber. Experiments were performed at room
temperature (∼23 °C).
Electronic signals were ampliﬁed using an Axopatch 200B
(Molecular Devices) with digitization performed with a Digidata
1440 (Axon Instruments). A low-pass 2 kHz Bessel ﬁlter was applied
upon recording with 10 kHz sampling rate. Clampex and Clampﬁt
(Molecular Devices) and Microsoft Excel were used for recording and
data analysis, respectively. For residual current determination, the
single-channel search function of Clampﬁt was employed. Contour
plots were made with Origin (OriginLab).
Dwell times (τoff) and interevent times were calculated by ﬁtting
exponential functions to cumulative distributions. Numbers are mean
± SD from at least three independent recordings.
For real-time measurements, E2 blockades were counted in 3 min
intervals with 0.5 min overlaps. The concentration of E2 at any given
time point was obtained by multiplying the fraction of E2 of the total
number of blockades (#E2/(#E2 + #E2Ub)) by the initial
concentration of E2 (160 nM). Origin (OriginLab) was used for
linear ﬁttings for initial rates.
Mass Spectrometric Analysis. The Coomassie-stained E2Ub
band was excised from gel and submitted for MS analysis. The gel
fragment was washed with 100 mM ammonium bicarbonate and
acetonitrile, resuspended in 100 mM ammonium bicarbonate, and
proteolytic treatment was performed using trypsin. Peptides were
extracted with 75% acetonitrile and 25% H2O (5% formic acid in
water) and analyzed by nanoliquid chromatography/tandem mass
spectrometry (nLC-MS/MS).46 MS data were analyzed with PEAKS
7.0 software (Bioinformatics Solutions Inc.).
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